Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes, obesity and cardiovascular health, yet some patients remain hesitant to start these therapies due to perceptions that they are new or unproven. This commentary equips clinicians with practical counseling strategies to reframe the newness narrative and address long-term safety ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs)along with the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA tirzepatideare widely acknowledged for their efficacy in managing both type 2 diabetes mellitus and obesity, with expanding indications in cardiometabolic risk reduction. While their glycemic, weight-lowering, and cardiovascular benefits are well established ...
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Receptor Agonist Handling And Patient Safety.
Understanding the weight rebound phenomenon after GLP-1 discontinuation is essential for counseling patients on realistic expectations and the need for sustained lifestyle modifications or continued pharmacotherapy, which directly impacts treatment planning and patient adherence.
OBJECTIVES: To descriptively characterize real world adverse event reporting associated with GLP 1 receptor agonists in the United States using FAERS data from 2015 to 2025, with a focus on patient demographics, reporter type, indications, clinical outcomes, and frequently reported reaction categories across individual GLP 1 agents.
Abstract What is known and objective In recent years, glucagonlike peptide1 receptor agonists (GLP1 RAs) including onceweekly (QW) formulations have been incorporated into type 2 diabetes (T2D) clinical guidelines, making it essential that pharmacists and healthcare professionals (HCPs) have a clear understanding of their safety profiles. Currently, three QW GLP1 RAs are ...
Common Side Effects of GLP-1 Agonists. GLP-1 receptor agonists, such as semaglutide and tirzepatide, are effective medications for managing obesity and type 2 diabetes.
Clinicians increasingly prescribe glucagon-like peptide 1 (GLP1) receptor agonists (GLP1-RAs) and dual GLP1 and glucose-dependent insulinotropic polypeptide receptor agonists to treat these and other conditions.
